• The study randomized 229 patients with well-differentiated metastatic or locally advanced inoperable midgut neuroendocrine tumors to receive 4 intravenous administrations (every 8 weeks) of the peptide receptor radionuclide therapy (plus best supportive care, including standard-dose octreotide long-acting repeatable [LAR]) or high-dose octreotide LAR alone. (ascopost.com)
  • The approval of Lutathera was originally based on the pivotal NETTER-1 trial, which demonstrated highly significant and clinically meaningful PFS prolongation for patients treated with Lutathera in combination with long-acting octreotide versus high-dose (60 mg) long-acting octreotide for SSTR-positive, inoperable midgut neuroendocrine tumors (NETs) who were progressing despite standard treatment 3-4,9 . (novartis.com)
  • A phase II trial for the use of 90Y DOTA-TOC for patients with metastatic carcinoid, where octreotide treatment was no longer effective, also reported results in 2010. (wikipedia.org)
  • In 2015, the hospital's nuclear medicine centre was the first in the province to treat inoperable and metastatic neuroendocrine tumours with the Lutetium (177) Lu-DOTATATE procedure. (netcare.co.za)
  • Lutathera ® (INN: lutetium ( 177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs, including foregut, midgut and hindgut neuroendocrine tumors in adults and in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults 1 0 - 1 1 . (novartis.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (blogspot.com)
  • Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (blogspot.com)
  • Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. (blogspot.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). (blogspot.com)
  • Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. (blogspot.com)
  • Lu-177 dotatate , a peptide receptor radionuclide therapy, consists of the somatostatin analog octreotate connected with the beta- and gamma-emitting radiopharmaceutical lutetium-177. (ascopost.com)
  • As both speakers indicated, peptide receptor radionuclide therapy (90-Y dotatate or Lu-177 dotatate ) is recommended for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors that are progressing despite standard-dose long-acting somatostatin analog therapy and for pancreatic neuroendocrine tumors progressing after somatostatin analog therapy or everolimus (Afinitor). (ascopost.com)
  • First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose long-acting octreotide alone 1,2 . (novartis.com)
  • The somatostatin analogs (SSAs) octreotide and lanreotide are used to control carcinoid symptoms and tumor progression in advanced inoperable disease. (medscape.com)
  • Patients with diarrhea that is not controlled with somatostatin analog therapy can be treated with telostristat ethyl, a tryptophan hydroxylase inhibitor. (medscape.com)
  • Stereotactic body radiation therapy (SBRT) offers a new treatment option for older patients with inoperable kidney tumors. (auntminnie.com)
  • NETTER-2 (NCT03972488) is an open-label, multi-center, randomized, comparator-controlled Phase III trial assessing whether Lutathera plus long-acting octreotide when taken as a first line treatment can prolong PFS in patients with high-proliferation rate tumors (G2 and G3), compared to treatment with high-dose (60 mg) long-acting octreotide 2 . (novartis.com)
  • If a patient is thought to have carcinoid syndrome, blood and urine tests must be performed to determine levels of bioactive substances secreted by carcinoid tumors. (medscape.com)
  • In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium Lu-177 dotatate (Lutathera) led to markedly longer progression-free survival and significantly higher response rates vs the control arm. (ascopost.com)
  • Turkish radiopharmaceutical company Eczacıbaşı-Monrol plans to expand its Lutetium-177 (Lu-177) production capacity. (auntminnie.com)
  • In the largest series of patients treated with Lu-177 dotatate (from Rotterdam, The Netherlands), median progression-free survival stretched to almost 3 years, 4 revealed Dr. Strosberg, although some patients did not have progressive disease at entry. (ascopost.com)
  • Basel, September 25, 2023 - Today, Novartis announced the Phase III NETTER-2 trial with Lutathera ® (INN: lutetium ( 177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) met its primary endpoint. (novartis.com)
  • These positive results for Lutathera are quite remarkable and they represent the potential for radioligand therapy to make a meaningful impact for newly diagnosed patients living with advanced GEP-NETs," said Jeff Legos, Executive Vice President, Global Head of Oncology Development at Novartis. (novartis.com)
  • Gallium-68 (Ga-68) FAPI-PET/CT imaging -- a highly accurate experimental approach for detecting cancer -- may further improve outcomes for patients undergoing radiation therapy, according to a recent analysis by German researchers. (auntminnie.com)
  • Prostate cancer patients with locoregional lymph node disease at diagnosis (N1M0) still have a limited prognosis despite the improvements provided by aggressive curative intent multimodal locoregional external beam radiation therapy (EBRT) with systemic androgen deprivation therapy (ADT). (biomedcentral.com)
  • Based on this assumption, more and more N1M0 patients are now offered high-dose locoregional external beam radiation therapy (EBRT) with a boost to all visible tumour lesions in the pelvic area combined with 2-3 years concurrent and adjuvant androgen deprivation therapy (ADT). (biomedcentral.com)
  • Food and Drug Administration expanded the indication of pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. (blogspot.com)
  • Malignant carcinoid syndrome occurs in fewer than 10% of patients with a carcinoid tumor. (medscape.com)
  • Exploring the use of radioligand therapies in earlier lines of treatment for patients with cancer is part of our larger, collaborative effort to precisely deliver novel treatment modalities directly to the cancer cells to improve patient outcomes. (novartis.com)
  • Evaluate patient-reported outcomes measures during the natural course of HCC and management with HRQoL questionnaires 3. (rwjbh.org)
  • However, some NETs are associated with rapid progression and poor prognosis and in many cases, diagnosis is delayed until patients have advanced disease 5-7 . (novartis.com)
  • Even though NETs are a rare (orphan) disease, their incidence has grown over 500% in the last three decades 5-8 and there is an urgent need for additional treatment options for patients newly diagnosed with inoperable or advanced disease. (novartis.com)
  • In the past, prostate cancer patients with nodal metastases were not considered for curative treatment, based on the assumption that cure was neither feasible nor beneficial, based on the hypothesis that patients with lymph node metastases are affected by a systemic disease. (biomedcentral.com)
  • These developments are leading to higher confidence that at least some of the current prostate cancer patients staged N1M0 may not yet have systemic disease, and therefore may potentially benefit from an aggressive multimodal treatment approach. (biomedcentral.com)
  • Despite the improvements provided by aggressive multimodal locoregional EBRT with systemic long-term ADT, patients with N1M0 disease still have a suboptimal prognosis. (biomedcentral.com)
  • a patient with ovarian teratomas, whose secretory products enter into the systemic circulation, may present with this syndrome without liver metastasis. (medscape.com)
  • He revealed on the "BBC Breakfast" show that after he went public with his diagnosis, scientist Christopher Evans (whom Andy calls the "Elon Musk of cancer") reached out to him to offer an innovative drug treatment - "a nuclear medicine, Lutetium-177, which is targeted so it only sees cancer cells," the rocker explained. (newcelebworld.com)
  • With these results, NETTER-2 is Lutathera's second Phase III trial showing clinically meaningful results for patients 2,4 . (novartis.com)
  • Lutetium-177 labelled edotreotide (177Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs. (wikipedia.org)
  • In the meantime, an expanded-access program is available through the manufacturer, and a list of treatment sites is available on the patient association website. (ascopost.com)
  • for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (blogspot.com)
  • In this role, he will expand his already extensive work in modernizing American healthcare, including efforts to improve patient access to high-quality care through alternative payment models," ASTRO said in a statement. (auntminnie.com)
  • A phase I clinical trial of yttrium-90 labelled edotreotide concluded in 2011, aiming to investigated effects in young cancer patients (up to 25 years of age). (wikipedia.org)
  • I would particularly like to thank the people who have been with Netcare uMhlanga Hospital since its inception, for their loyalty and helping to maintain the institutional knowledge that is integral to our approach to caring for our patients. (netcare.co.za)
  • With uMhlanga developing rapidly into an important economic hub over this period, the hospital also expanded its facilities, capacity and services considerably to keep pace with the growing demand for private hospital care, without compromising on the personalised care its patients first received when the facility opened its doors 20 years ago. (netcare.co.za)
  • Each hospital has a personality of its own, and Netcare uMhlanga Hospital has made a name for itself among patients, visitors, staff and doctors alike with its professional yet friendly brand of care," notes the general manager, Marc van Heerden. (netcare.co.za)
  • In the NETTER-1 study, the most common grade 3-4 adverse reactions occurring with a greater frequency (at least 4%) among patients receiving lutetium Lu 177 dotatate with long-acting octreotide compared to patients receiving high-dose octreotide alone included lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea and elevated AST (5% each), and increased ALT, hyperglycemia, and hypokalemia (4% each). (fda.gov)
  • BARCELONA-In patients with inoperable progressive pancreatic cancer, a targeted radionuclide, lutetium-octreotate (OCLU), shows nearly double the 12-month progression-free survival (PFS) compared with sunitinib, researchers report. (medscape.com)
  • At the ERASMUS MC, lutetium Lu 177 dotatate was initially provided as expanded access under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. (fda.gov)
  • Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. (nih.gov)
  • The attraction for the same receptor binding with radioactive isotopes such as Y-90 or lutetium-177 ( 177 Lu) for treatment purposes is referred to as peptide receptor radionuclide therapy (PRRT). (targetedonc.com)
  • Lutetium-177 is a radionuclide substance that emits damaging radiation which will destroy cancer cells. (sunwaycancercentre.com)
  • . "Targeted Alpha-emitter Therapy (TAT) is the wave of the future in nuclear oncology and has a tremendous potential to treat patients with NET and overcome some of the limitations of current Peptide Receptor Radionuclide Therapy (PRRT) " said Dr. Ebrahim S. Delpassand, Chairman and CEO of RadioMedix, sponsor of the trial. (ronnyallan.net)
  • Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours. (cnets.ca)
  • Lutetium Lu 177 dotatate, the first peptide receptor radionuclide therapy, was approved by the US Food and Drug Administration in 2018 for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (medscape.com)
  • Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with neuroendocrine neoplasms. (snmjournals.org)
  • The findings come from the phase 2 OCLURANDOM trial, which investigated the antitumor efficacy of peptide receptor radionucleotide therapy (PRRT) with OCLU in previously treated patients with unresectable progressive pancreatic neuroendocrine tumors (NETs). (medscape.com)
  • It is the first randomized trial of PRRT in patients with advanced, progressive, somatostatin receptor-expressing (SSTR+) pancreatic NETs, the clinical trial record says. (medscape.com)
  • This could change the practice treatment paradigm, with PRRT used prior to sunitinib in unresectable progressive advanced SSTR+ pancreatic NET patients, although ongoing randomized trials enrolling advanced patients will help to confirm these results," said study co-investigator David Taïeb, MD, from La Timone Hospital, Aix-Marseille University, Marseille, France, who presented the work at European Association of Nuclear Medicine (EANM) 2022. (medscape.com)
  • Stopping treatment was rare in the PRRT patients," he said. (medscape.com)
  • A recent phase 1 trial (NCT03466216) involving 20 patients with histologically confirmed NETs, prior positive SSA scans, and no prior history of PRRT, 177 Lu, or Y-90 therapy received 4 cycles of 212 Pb-DOTAMTATE administered at 8-week intervals. (targetedonc.com)
  • This section is for doctors who are considering the selection of PRRT to treat one of their patients. (prrtinfo.org)
  • From the scant ' patient understandable ' information currently available, it would appear that alpha therapy has the potential to be more targeted and less toxic than beta PRRT - to me that seems like it would be able to target smaller tumours. (ronnyallan.net)
  • All patients treated from October 2002 until March 2016 at the Zentralklinik Bad Berka with at least 3 administrations of PRRT (maximal interval of 6 mo between consecutive administrations) were included. (snmjournals.org)
  • Data were collected in 5 categories: general patient characteristics, tumor characteristics, prior treatments, radioisotope used for PRRT, and blood chemistry. (snmjournals.org)
  • Lutetium-177 labelled edotreotide (177Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs. (wikipedia.org)
  • Pluvicto is a radiopharmaceutical (a drug with a trace of radioactivity) that contains the active ingredient lutetium (177Lu) vipivotide tetraxetan. (medsurgeindia.com)
  • As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. (cnets.ca)
  • Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313). (prrtinfo.org)
  • Patients must have had progressive disease over the previous 12 months and been previously treated with one line of cytotoxic chemotherapy or everolimus or somatostatin analogues. (medscape.com)
  • However, three patients discontinued everolimus because of cardiac and/or pulmonary adverse events, which led to two deaths. (medscape.com)
  • no patients receiving high-dose octreotide LAR developed myelodysplastic syndrome. (fda.gov)
  • A phase I clinical trial of yttrium-90 labelled edotreotide concluded in 2011, aiming to investigated effects in young cancer patients (up to 25 years of age). (wikipedia.org)
  • For patients NETs who have hepatic disease, which is about 40% to 90% of patients with NETs upon presentation, treatment with yttrium-90 (Y-90) is also an option. (targetedonc.com)
  • Yttrium 90 (Y-90) and Lutetium 177 (Lu-77) are the most common used radionuclides. (sunwaycancercentre.com)
  • This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on a somatostatin analogue and is unresectable (not removable by surgery). (cnets.ca)
  • Eligible patients include those with progressed SSR+ midgut (defined as jejunoileum and proximal in the NETTER-1 trial) NETs and good performance status. (cnets.ca)
  • These measures are designed to prevent hypoglycemia and, in patients with malignant tumors, to reduce the tumor burden. (medscape.com)
  • Pinnacle Biologics, Bannockburn, IL, USA) for the palliation of malignant dysphagia in esophageal malignancy and 2003 as an alternative to esophagectomy in patients with high-grade dysplasia (HGD) in patients with Barrett's esophagus. (ijgii.org)
  • The tumor is inoperable (it cannot be treated surgically). (medsurgeindia.com)
  • When used to allow neolumen formation when treating high-risk or surgically unresectable patients with dysphagia, retreatment is often undertaken with an additional light application 48 hours after the initial procedure. (ijgii.org)
  • The hypothesis was that the OCLU arm would assume a 25-percentage point increase (from 35% to 60%) in the 12-month PFS rate, and if at least 19 of 40 patients showed no progression or death at 12 months, OCLU would be considered effective, explained Taïeb. (medscape.com)
  • The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. (researcherprofiles.org)
  • Once Lutetium-177 PSMA is infused into a patient's bloodstream, it will target and bind to PSMA receptors on prostate cancer cells. (sunwaycancercentre.com)
  • Damaging radiation from the Lutetium-177 will, over time, result in death of the prostate cancer cells. (sunwaycancercentre.com)
  • Unfortunately, the majority of patients with brain metastases experience cognitive (such as learning and memory) deterioration after WBRT. (mayo.edu)
  • Conducted across 10 French expert centers, the OCLURANDOM trial, the first of its kind in this patient group, enrolled patients over 5 years and had a median follow-up of 40 months. (medscape.com)
  • Patients were allowed to cross over to dacarbazine after progression and had median survival of 11.9 months. (medscape.com)
  • In total, 782 patients were included, with a median follow-up of 36 mo. (snmjournals.org)
  • In Phase 2, patients will be randomized in a 1:1 ratio to the combination of ivaltinostat and capecitabine or to capecitabine monotherapy. (researcherprofiles.org)
  • these patients should be progressive under Octreotide LAR. (prrtinfo.org)
  • Most patients had grade 2 or 3 pancreatic NETs. (medscape.com)
  • The ORR was 16% (n=58), including 3 complete responses in this subset of 360 patients with GEP-NETs who were assessed according to RECIST criteria. (fda.gov)
  • 2 The following treatments are choices available for patients with well-differentiated NETs. (targetedonc.com)
  • In 2018, RadioMedix Inc. and Orano Med initiated the Phase 1 trial for AlphaMedix TM in patients with somatostatin receptor (SSTR) positive Neuroendocrine Tumors (NETs) - an NIH supported trial. (ronnyallan.net)
  • Ajaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors. (targetedonc.com)
  • What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? (researcherprofiles.org)
  • 2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? (researcherprofiles.org)
  • Grade 3 to 4 adverse events occurred in 45 of the 84 total patients (53%): 18 (44%) in the OCLU arm and 27 (63%) in the sunitinib arm. (medscape.com)
  • The doctor may decide to delay, change, or discontinue Pluvicto medication in India based on the results of these tests and any adverse reactions that the patient may experience. (medsurgeindia.com)
  • The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts. (researcherprofiles.org)
  • More than 25% of patients had liver involvement. (medscape.com)
  • a patient with ovarian teratomas, whose secretory products enter into the systemic circulation, may present with this syndrome without liver metastasis. (medscape.com)
  • This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site (place where it started) to the brain. (mayo.edu)
  • A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile. (researcherprofiles.org)
  • Of patients with insulinoma, 50% may benefit from the somatostatin analog octreotide to prevent hypoglycemia. (medscape.com)
  • The mean patient age was 63 years, and 52% of patients were female. (medscape.com)
  • All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere. (mayo.edu)
  • In patients with insulinoma and a negative scan finding, somatostatin decreased insulin levels significantly and lowered the incidence of hypoglycemic events. (medscape.com)